tert-butyl N-[2-[(4-nitrophenyl)sulfonylamino]ethyl]carbamate | 902775-89-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl N-[2-[(4-nitrophenyl)sulfonylamino]ethyl]carbamate
• 英文别名: tert-butyl N-[2-(4-nitrobenzenesulfonamido)ethyl]carbamate
• CAS: 902775-89-7
• 化学式: C₁₃H₁₉N₃O₆S
• 分子量: 345.376
• InChiKey: RKAFEOZZTVEPLP-UHFFFAOYSA-N

物化性质

• 密度：
  1.311±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  139
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  tert-butyl N-[2-[(4-nitrophenyl)sulfonylamino]ethyl]carbamate 在 5%-palladium/activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、300.01 kPa 条件下， 反应 3.0h， 以93%的产率得到tert-butyl N-[2-[(4-aminophenyl)sulfonylamino]ethyl]carbamate
  参考文献：
  名称：

  将人造亚胺还原酶固定在二氧化硅纳米粒子中可改善其性能

  摘要：

  在二氧化硅纳米颗粒中固定和保护人造亚胺还原酶可提高其活性并保护其免受各种变性应力的影响。

  DOI：

  10.1039/c6cc04604e
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 11.0h， 生成 tert-butyl N-[2-[(4-nitrophenyl)sulfonylamino]ethyl]carbamate
  参考文献：
  名称：

  一种1,4-萘醌类衍生物及其制备方法和应用

  摘要：

  本发明涉及一种1,4‑萘醌类衍生物及其制备方法和应用，本发明首次合成并发现该类化合物具有良好的抑制人结肠癌细胞(SW480和HCT116)的活性，在抗肿瘤药物开发和应用方面具有潜在价值；同时本发明对所合成的化合物进行了α‑葡萄糖苷酶抑制活性，实验结果表明该类化合物也具有一定的α‑葡萄糖苷酶抑制活性，说明该类化合物在治疗糖尿病药物的开发与应用方面也具有广阔前景。

  公开号：

  CN108752243B

文献信息

• Optical Control of Mitosis with a Photoswitchable Eg5 Inhibitor
  作者：Anna C. Impastato、Andrej Shemet、Nynke A. Vepřek、Gadiel Saper、Henry Hess、Lu Rao、Arne Gennerich、Dirk Trauner

  DOI：10.1002/anie.202115846

  日期：2022.2.21

  The optical control of a mitotic kinesin, Eg5, was achieved through an azobenzene analog of EMD-534085. Under UV light conditions, HeLa cells undergo mitotic arrest, as evidenced by the formation of a monopolar spindle.

  有丝分裂驱动蛋白 Eg5 的光学控制是通过 EMD-534085 的偶氮苯类似物实现的。在紫外线条件下，HeLa 细胞发生有丝分裂停滞，单极纺锤体的形成证明了这一点。
• Artificial Transfer Hydrogenases Based on the Biotin−(Strept)avidin Technology:  Fine Tuning the Selectivity by Saturation Mutagenesis of the Host Protein
  作者：Christophe Letondor、Anca Pordea、Nicolas Humbert、Anita Ivanova、Sylwester Mazurek、Marjana Novic、Thomas R. Ward

  DOI：10.1021/ja061580o

  日期：2006.6.1

  Incorporation of biotinylated racemic three-legged d(6)-piano stool complexes in streptavidin yields enantioselective transfer hydrogenation artificial metalloenzymes for the reduction of ketones. Having identified the most promising organometallic catalyst precursors in the presence of wild-type streptavidin, fine-tuning of the selectivity is achieved by saturation mutagenesis at position S112. This choice for the genetic optimization site is suggested by docking studies which reveal that this position lies closest to the biotinylated metal upon incorporation into streptavidin. For aromatic ketones, the reaction proceeds smoothly to afford the corresponding enantioenriched alcohols in up to 97% ee (R) or 70% (S). On the basis of these results, we suggest that the enantioselection is mostly dictated by CH/pi interactions between the substrate and the eta(6)-bound arene. However, these enantiodiscriminating interactions can be outweighed in the presence of cationic residues at position S112 to afford the opposite enantiomers of the product.
• [EN] CDK INHIBITORS AND PHARMACEUTICAL USES THEREOF<br/>[FR] INHIBITEURS DE CDK ET LEURS UTILISATIONS PHARMACEUTIQUES
  申请人：[en]RISEN (SUZHOU) PHARMA TECH CO., LTD.

  公开号：WO2023205892A1

  公开（公告）日：2023-11-02

  The disclosure relates to bifunctional CDK-modulating compounds having the structure W-L-T, where W is a targeting group (1a), 1b) and (1c), that binds specifically to a CDK protein, T is an E3-ligase binding group, and L is absent or is a bivalent linking group that connects W and T together via a covalent linkage. Compounds and pharmaceutical compositions thereof can promote degradation of one or more CDK protein in a cell and are thus useful for treating, inhibiting, and preventing CDK-associated diseases, disorders and conditions, including cancers. Formulas (1a), (1b) & (1c):
• [EN] DERIVATIVES OF ARYL HYDROCARBON RECEPTOR AGONISTS<br/>[FR] DÉRIVÉS D'AGONISTES DU RÉCEPTEUR DE L'ARYL-HYDROCARBONE
  申请人：[en]AZORA THERAPEUTICS, INC.

  公开号：WO2023060268A1

  公开（公告）日：2023-04-13

  A compound having one of the following structures of Formula (IV) or (V): or a stereoisomer, salt, or tautomer thereof, wherein R1, R2, R3, R4, R5R6, R7, R8, R10, R11aR11b, R12aR12b, X, Y, and Z are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.